When something becomes hard to get and expensive, criminals see an opportunity.
A medication born to steady the blood sugar of diabetic patients became, almost overnight, a cultural phenomenon — and the consequences of that transformation are now being measured in empty pharmacy shelves and counterfeit syringes. Across Europe, the viral appetite for Ozempic as a weight-loss tool has left those who need it most without access, while criminal networks have moved into the vacuum with dangerous imitations. It is a story as old as scarcity itself: when desire outpaces supply, the vulnerable pay twice.
- Celebrity endorsements turned a diabetes medication into a weight-loss sensation, triggering demand so intense that over 900 essential medicines — Ozempic among them — vanished from European pharmacy shelves.
- Counterfeit Ozempic injections, labeled in German and traced to companies in Germany and Austria, began circulating across the EU and UK, landing several people in Austrian hospitals.
- The real drug carries serious risks of its own — pancreatitis, kidney damage, vision changes, and a possible link to thyroid cancer — making the unknown contents of a fake injection a compounded danger.
- Regulatory agencies across Belgium, the UK, and the EU have issued alerts, while manufacturer Novo Nordisk investigates a surge in illegal online sales and urges consumers to scrutinize every pen they receive.
- With no guarantee that counterfeits were kept out of legitimate supply chains, the public has effectively been deputized as the last line of defense against their own harm.
Ozempic was designed for a specific and serious purpose: helping adults with type 2 diabetes regulate blood sugar when diet and exercise were not enough. That purpose held until late 2022, when celebrities began speaking openly about using semaglutide — the drug's active ingredient — to lose weight. Elon Musk mentioned it. Amy Schumer spoke about it. The drug went viral, and pharmacies across Europe could not keep pace with what followed.
The fallout was swift and uneven. Spanish pharmacies were among the first to report shortages, but the crisis spread continent-wide. Pharmaceutical associations documented the disappearance of more than 900 essential medicines, with Ozempic prominent among them. Diabetic patients — the people the drug was made for — found themselves unable to fill prescriptions. In August 2023, Spain approved Wegovy, a drug designed specifically for weight loss, hoping to redirect demand and relieve pressure on the original supply.
Scarcity, however, invited something worse. In October 2023, the European Medicines Agency warned that counterfeit Ozempic pens were circulating in the EU and UK. The fakes carried real serial numbers — a detail that made them traceable once identified — and had moved through companies in Germany and Austria before reaching multiple countries. In Austria, several people were hospitalized. Belgium and the UK issued their own warnings. Regulators found no evidence the counterfeits had entered legitimate pharmacy channels, but the risk was undeniable.
The authentic drug already carries a serious list of warnings: nausea, vomiting, kidney damage, acute pancreatitis, severe allergic reactions, vision changes, and a manufacturer-noted concern about thyroid tumors observed in animal studies. A counterfeit version adds the unknown to all of that. Novo Nordisk acknowledged the surge in illegal online sales, pledged to investigate each case, and urged consumers to verify the appearance and labeling of every injection before use.
What crystallized across Europe was a collision between aspiration and necessity. A drug built to manage a chronic illness became a shortcut to thinness, stripped from the people who depended on it, and replaced in some hands by something dangerous and unknown. Regulatory agencies, unable to inspect every transaction, asked the public to become their own guardians — to look closely, to question, and to return anything that did not seem right.
Ozempic was designed to help people manage type 2 diabetes. It works by regulating blood sugar in adults whose diet and exercise alone cannot do the job. Then, in late 2022, something shifted. Celebrities began talking openly about using semaglutide—the active ingredient in Ozempic—to lose weight. Elon Musk mentioned it. Amy Schumer spoke about it. The drug went viral. Suddenly, everyone wanted it, and the pharmacies could not keep up.
The consequences rippled outward quickly. By the end of 2022, Spanish pharmacies began reporting shortages. The problem was not unique to Spain. Across Europe, the demand for weight loss had created a genuine crisis in the supply of a medication that diabetic patients actually needed. Pharmaceutical associations documented the absence of more than 900 essential medicines from shelves, and Ozempic was among them. The Spanish Medicines Agency issued warnings about the scarcity. In August 2023, they approved a separate drug called Wegovy, designed specifically for weight loss, hoping to redirect demand and ease pressure on the original supply.
But the shortage created a darker problem. When a medication becomes scarce and desirable, counterfeiters move in. In October 2023, the European Medicines Agency issued an alert: fake Ozempic injections were circulating in the European Union and the United Kingdom. The counterfeit pens were labeled in German and had been imported through companies in Germany and Austria. They were discovered because they carried real serial numbers—a detail that should have made them seem legitimate but instead made them easier to track. Once identified, they were marked as inactive.
The fake injections reached multiple countries. In Austria, several people were hospitalized after using them. Belgium's medicines regulator issued its own warning about counterfeits in circulation. The United Kingdom reported cases. Spain, notably, was not among the affected nations, though the threat remained real across the continent. The European Medicines Agency found no evidence that the counterfeits had been dispensed through legitimate pharmacies, and no confirmed patient harm had been documented—but the risk was unmistakable.
The side effects of legitimate Ozempic are substantial enough without adding the unknown dangers of a fake version. The drug's official documentation lists common problems: nausea, vomiting, diarrhea, constipation. But it also warns of more serious complications—kidney damage, severe allergic reactions, acute pancreatitis, dangerously low blood sugar, vision changes. The manufacturer's own website notes that animal studies suggested possible thyroid tumors and cancer, which is why the drug is contraindicated for anyone with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome.
Novo Nordisk, the manufacturer, acknowledged the crisis in a statement. They reported a significant surge in illegal online sales of their product. Each case, they said, was being investigated and reported to authorities. The company urged consumers to verify that their injections were authentic, to check the labeling and appearance against the genuine product, and to return anything suspicious to a pharmacy.
What emerged was a collision between celebrity culture and public health. A medication created to treat a chronic disease became a status symbol, a shortcut to thinness. The demand stripped shelves of a drug that diabetic patients depended on. The shortage created an opening for criminals. And now, across Europe, people were being warned to inspect their medications carefully, to distrust what they had bought, to question whether what they held in their hands was real or a dangerous imitation. The regulatory agencies had no choice but to ask the public to become their own inspectors, their own guardians against harm.
Citas Notables
Novo Nordisk reported a significant surge in illegal online sales of their product, with each case being investigated and reported to authorities.— Novo Nordisk (manufacturer statement)
La Conversación del Hearth Otra perspectiva de la historia
Why did Ozempic become so desirable for weight loss when it was never approved for that purpose?
Because it works. Celebrities used it, talked about it publicly, and suddenly everyone saw it as a shortcut to the body they wanted. The drug genuinely helps people lose weight, even though that's not what it was designed for. Once that became visible, demand exploded.
And that demand created the shortage?
Exactly. Pharmacies couldn't stock enough for the people who actually needed it for diabetes. The supply was finite, but the demand became infinite. That's when the system breaks.
What made counterfeiting inevitable?
Scarcity plus high demand plus a product people will pay for without asking too many questions. When something becomes hard to get and expensive, criminals see an opportunity. They made fake pens with real serial numbers to make them look legitimate.
How dangerous are the counterfeits compared to the real drug?
We don't know exactly. The real drug already carries serious risks—pancreatitis, kidney problems, thyroid cancer. A fake version could be anything. It could be inert, or it could be contaminated, or it could contain something entirely different. Several people in Austria ended up in hospitals.
What's the lesson here?
That viral demand for a medication can destabilize the entire system. It harms the people the drug was meant to help, creates opportunities for criminals, and puts people at risk of serious harm. The regulatory agencies can warn people to check their medications, but they can't solve the underlying problem: too many people want something that isn't available.
So what happens next?
The agencies keep investigating. Novo Nordisk keeps reporting illegal sales. Pharmacies keep warning customers. But the demand for weight loss doesn't disappear just because the supply is limited. That tension remains.